Three key lessons for digital health investors from the demise of Babylon Health
When Babylon Health listed in New York in 2021, the telehealth company was valued at $4.2bn. Within a year later the stock price collapsed and it later filed for bankruptcy. The company’s British assets sold for only £500k. We look at three key lessons for digital health investors.
Operators of acute hospitals, day-surgery and outpatient facilities including opthalmic, imaging centres, cancer and radiotherapy clinics, and ambulance services
Market opportunities for surgical ophthalmic equipment and products
Johan Ottosson, Senior Associate and Dr. Victor Chua, Senior Partner see significant opportunities in the market for surgical ophthalmic equipment and products
Johan Ottosson, Senior Associate and Dr. Victor Chua, Senior Partner see significant opportunities in the market for surgical ophthalmic equipment and products
Radiopharmaceuticals - where hot molecules meet cold capital
Radiopharmaceuticals remains a hot topic in 2026, with continued investment from both big and mid-sized pharma, and private equity in the last twelve months. Will Johnson, engagement manager, Lakshiv Dhingra, clinical fellow, and Victor Chua, Partner, at Mansfield Advisors outline key developments and potential asset classes for private equity investors considering the sector.
Johan Ottosson, Senior Associate and Dr. Victor Chua, Senior Partner see significant opportunities in the market for surgical ophthalmic equipment and products
Strategy for the side of healthcare that pays for it
We advise governments, regulators, insurers and health systems on how care is funded, organised and bought. Our team includes doctors and people who have led inside health systems. So we know the machinery from the inside.
Buying better care with money that never stretches
Every health system is trying to solve the same problem: how to buy better care with money that never stretches far enough. Insurers face rising claims and medical inflation. Public systems face waiting lists and workforce gaps. Both are changing how they commission, contract and pay.
We work on that machinery. We advise payors on strategy and product, governments and regulators on policy and system design, and investors on businesses whose fortunes turn on how the system pays.